Fuso Pharmaceutical Industries,Ltd. Logo

Fuso Pharmaceutical Industries,Ltd.

Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.

4538 | T

Overview

Corporate Details

ISIN(s):
JP3823600006
LEI:
Country:
Japan
Address:
大阪市中央区道修町一丁目7番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fuso Pharmaceutical Industries, Ltd. is a manufacturer and seller of pharmaceuticals and medical equipment. Established in 1950, the company specializes in essential medical products, with a core portfolio centered on dialysis-related drugs, infusions, injections, and transfusion fluids. Fuso is actively involved in the research and development of new medicines, maintaining a pipeline of drugs in various clinical trial stages. The company's operations are guided by its mission of "Supporting Life, Nurturing Life," providing critical healthcare solutions to medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 04:14
Interim Report
確認書
Japanese 9.3 KB
2025-11-12 04:08
Interim Report
半期報告書-第103期(2025/04/01-2026/03/31)
Japanese 194.0 KB
2025-06-26 04:32
Post-Annual General Meeting Information
臨時報告書
Japanese 27.4 KB
2025-06-24 08:02
Governance Information
内部統制報告書-第102期(2024/04/01-2025/03/31)
Japanese 25.2 KB
2025-06-24 08:01
Registration Form
確認書
Japanese 9.4 KB
2025-06-24 08:00
Registration Form
有価証券報告書-第102期(2024/04/01-2025/03/31)
Japanese 1.0 MB
2025-06-03 10:03
Capital/Financing Update
臨時報告書
Japanese 22.6 KB
2025-05-28 09:44
Legal Proceedings Report
臨時報告書
Japanese 23.6 KB
2024-11-12 07:02
Interim Report
確認書
Japanese 9.3 KB
2024-11-12 07:01
Interim Report
半期報告書-第102期(2024/04/01-2025/03/31)
Japanese 189.2 KB
2024-06-26 03:18
Post-Annual General Meeting Information
臨時報告書
Japanese 24.7 KB
2024-06-25 09:19
Governance Information
内部統制報告書-第101期(2023/04/01-2024/03/31)
Japanese 24.1 KB
2024-06-25 09:17
Registration Form
確認書
Japanese 9.4 KB
2024-06-25 09:04
Registration Form
有価証券報告書-第101期(2023/04/01-2024/03/31)
Japanese 1019.3 KB
2024-05-13 10:14
Regulatory News Service
臨時報告書
Japanese 23.1 KB

Automate Your Workflow. Get a real-time feed of all Fuso Pharmaceutical Industries,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuso Pharmaceutical Industries,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuso Pharmaceutical Industries,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea
007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea
293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden
APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea
291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America
APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America
AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America
ABUS
Arcellx, Inc. Logo
Engineering controllable cell therapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway
ABS

Talk to a Data Expert

Have a question? We'll get back to you promptly.